IGC PHARMA INC (IGC) Stock Price, Quote, News and Overview
NYSEARCA:IGC - NYSE Arca - US45408X3089 - Common Stock - Currency: USD
IGC Quote, Performance and Key Statistics
0.3747
-0.01 (-1.6%)
The current stock price of IGC is 0.3747 USD. In the past month the price increased by 20.87%. In the past year, price decreased by -18.54%.
IGC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 58.09 | 757.57B | ||
| JNJ | JOHNSON & JOHNSON | 15.6 | 377.32B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.73 | 306.33B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.57 | 239.06B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.49 | 222.42B | ||
| MRK | MERCK & CO. INC. | 10.74 | 210.10B | ||
| PFE | PFIZER INC | 7.9 | 144.12B | ||
| SNY | SANOFI-ADR | 10.67 | 118.22B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.45 | 96.34B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 77.46B | ||
| ZTS | ZOETIS INC | 25.86 | 69.30B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.67 | 46.98B |
Related stock screener links
About IGC
Company Profile
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 67 full-time employees. The company went IPO on 2006-04-13. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The firm operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. The company seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Company Info
IGC PHARMA INC
10224 Falls Road
Potomac MARYLAND 20854 US
CEO: Ram Mukunda
Employees: 67
Phone: 13019830998
IGC PHARMA INC / IGC FAQ
What is the stock price of IGC PHARMA INC today?
The current stock price of IGC is 0.3747 USD. The price decreased by -1.6% in the last trading session.
What is the ticker symbol for IGC PHARMA INC stock?
The exchange symbol of IGC PHARMA INC is IGC and it is listed on the NYSE Arca exchange.
On which exchange is IGC stock listed?
IGC stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for IGC PHARMA INC stock?
6 analysts have analysed IGC and the average price target is 3.95 USD. This implies a price increase of 954.84% is expected in the next year compared to the current price of 0.3747. Check the IGC PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IGC PHARMA INC worth?
IGC PHARMA INC (IGC) has a market capitalization of 31.43M USD. This makes IGC a Nano Cap stock.
How many employees does IGC PHARMA INC have?
IGC PHARMA INC (IGC) currently has 67 employees.
What are the support and resistance levels for IGC PHARMA INC (IGC) stock?
IGC PHARMA INC (IGC) has a support level at 0.31 and a resistance level at 0.38. Check the full technical report for a detailed analysis of IGC support and resistance levels.
Is IGC PHARMA INC (IGC) expected to grow?
The Revenue of IGC PHARMA INC (IGC) is expected to grow by 16.45% in the next year. Check the estimates tab for more information on the IGC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IGC PHARMA INC (IGC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IGC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IGC, evaluating the profitability, health, valuation and growth aspects
- IGC PHARMA INC (IGC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IGC PHARMA INC (IGC) Sales and EPS estimates to see what analysts future expectations are.
- IGC PHARMA INC (IGC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IGC PHARMA INC (IGC) Insider and Institutional Ownership to learn about the owners and their transactions.
- IGC PHARMA INC (IGC) Stock Chart to make your own analysis
- IGC PHARMA INC (IGC) Latest news and press-releases to stay up to date.
Does IGC PHARMA INC (IGC) stock pay dividends?
IGC does not pay a dividend.
When does IGC PHARMA INC (IGC) report earnings?
IGC PHARMA INC (IGC) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of IGC PHARMA INC (IGC)?
IGC PHARMA INC (IGC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
What is the Short Interest ratio of IGC PHARMA INC (IGC) stock?
The outstanding short interest for IGC PHARMA INC (IGC) is 0.72% of its float. Check the ownership tab for more information on the IGC short interest.
IGC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IGC. When comparing the yearly performance of all stocks, IGC turns out to be only a medium performer in the overall market: it outperformed 49.87% of all stocks.
IGC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IGC. IGC has a bad profitability rating. Also its financial health evaluation is rather negative.
IGC Financial Highlights
Over the last trailing twelve months IGC reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 57.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.41% | ||
| ROE | -112.5% | ||
| Debt/Equity | 0.02 |
IGC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IGC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -5.89% and a revenue growth 16.45% for IGC